- |||||||||| lurasidone injection suspension (DSP-1349M) / Sumitomo Dainippon
PK/PD data, Preclinical, Journal: Antipsychotic lurasidone: Behavioural and pharmacokinetic data in C57BL/6 mice. (Pubmed Central) - Mar 31, 2021
This last result gives important data to adapt oral chronic administration of lurasidone with a more ethical perspective in comparison with chronic i.p. injections. This study brings tools to improve pharmacological validity of preclinical models of psychiatric diseases, and to adapt dosage of antipsychotics according to the route used.
- |||||||||| bromocriptine / Generic mfg., lurasidone oral / Generic mfg.
[VIRTUAL] FACIAL DYSTONIA MASQUERADING AS ANGIOEDEMA () - Nov 21, 2020 - Abstract #ACAAI2020ACAAI_658;
He had resolution of symptoms with no further episodes, and was discharged with follow up with his psychiatrist.Discussion We present a case of facial dystonia likely secondary to atypical antipsychotic use where tongue protrusion was initially managed as histaminergic angioedema. This case highlights the importance of identifying true angioedema in contrast to disorders mimicking angioedema.
- |||||||||| Retrospective data, Journal: Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia. (Pubmed Central) - May 17, 2020
The 95% effective doses and the doses equivalent to 1 mg of oral risperidone, respectively, were as follows: amisulpride for patients with positive symptoms, 537 mg/day and 85.8 mg; aripiprazole, 11.5 mg/day and 1.8 mg; aripiprazole LAI (lauroxil), 463 mg every 4 weeks and 264 mg; asenapine, 15.0 mg/day and 2.4 mg; brexpiprazole, 3.36 mg/day and 0.54 mg; haloperidol, 6.3 mg/day and 1.01 mg; iloperidone, 20.13 mg/day and 3.2 mg; lurasidone, 147 mg/day and 23.5 mg; olanzapine, 15.2 mg/day and 2.4 mg; olanzapine LAI, 277 mg every 2 weeks and 3.2 mg; paliperidone, 13.4 mg/day and 2.1 mg; paliperidone LAI, 120 mg every 4 weeks and 1.53 mg; quetiapine, 482 mg/day and 77 mg; risperidone, 6.3 mg/day and 1 mg; risperidone LAI, 36.6 mg every 2 weeks and 0.42 mg; sertindole, 22.5 mg/day and 3.6 mg; and ziprasidone, 186 mg/day and 30 mg...In chronic schizophrenia patients with acute exacerbations, doses higher than the identified 95% effective doses may on average not provide more efficacy. For some drugs, higher than currently licensed doses might be tested in further trials, because their dose-response curves did not plateau.
- |||||||||| lurasidone injection suspension (DSP-1349M) / Sumitomo Dainippon, Latuda (lurasidone oral) / Sumitomo Dainippon, Geodon (ziprasidone) / RaQualia, Meiji Seika, Pfizer
Preclinical, Journal: Adjunctive Lurasidone Suppresses Food Intake and Weight Gain Associated with Olanzapine Administration in Rats. (Pubmed Central) - Mar 26, 2019
: These findings support our hypotheses in that lurasidone, in addition to a lack of effect on acute food intake and short term weight gain, can reduce olanzapine-induced food intake and weight gain in rats. This indicates the drug to have an active anti-hyperphagic mechanism, rather than solely the absence of a drug-induced weight gain that is such a severe limitation of drugs such as olanzapine.
- |||||||||| lurasidone injection suspension (DSP-1349M) / Sumitomo Dainippon
Trial completion date, Trial primary completion date: A Study to Determine the Maximum Tolerated Dose of an Investigational Drug in Subjects With Schizophrenia (clinicaltrials.gov) - Mar 5, 2019
P1, N=40, Recruiting,
This indicates the drug to have an active anti-hyperphagic mechanism, rather than solely the absence of a drug-induced weight gain that is such a severe limitation of drugs such as olanzapine. Trial completion date: Oct 2019 --> Mar 2019 | Trial primary completion date: Oct 2019 --> Mar 2019
|
